Oxford BioDynamics Releases 2024 Annual Report Ahead of AGM

Oxford BioDynamics ( (GB:OBD) ) just unveiled an announcement.

Oxford BioDynamics Plc has published its 2024 Annual Report, available on its website, detailing its financial results and operations for the year. The report’s release comes ahead of the company’s Annual General Meeting scheduled for March 28, 2025. This announcement underscores the company’s ongoing commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.

More about Oxford BioDynamics

Oxford BioDynamics Plc is an international biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision clinical diagnostic tests for life-changing diseases. The company offers two main products: EpiSwitch® PSE, which enhances the predictive accuracy of prostate cancer screening, and EpiSwitch® CiRT, a predictive response test for immuno-oncology treatments. These tests are based on the proprietary EpiSwitch® 3D genomic biomarker platform. The company operates from headquarters in Oxford, UK, with additional facilities in Maryland, USA, and Penang, Malaysia.

YTD Price Performance: -66.00%

Average Trading Volume: 20,764,400

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £9.98M

For an in-depth examination of OBD stock, go to TipRanks’ Stock Analysis page.